SK Corp. Interim Dividend of 1,500 KRW per Share... 6 Consecutive Years of Interim Dividends Paid

Change in Articles of Incorporation to Invest After Confirming Dividends, First Application
Dividends to Be Paid to Shareholders as of the 10th of Next Month

SK Co., Ltd. announced on the 26th that it held a board meeting and resolved to pay an interim dividend of 1,500 KRW per share, the same as last year. This marks the sixth consecutive year of interim dividends since they began in 2018, with the total interim dividend amount for this year being approximately 83.6 billion KRW.

This interim dividend is the first to be paid after the amendment of the Articles of Incorporation at the shareholders' meeting in March, which allows investors to decide on their investments after confirming whether dividends will be paid and the amount of dividends. In January, the Financial Services Commission and the Ministry of Justice announced an improvement plan for dividend procedures recommending that the record date for year-end dividends be changed to after the dividend amount is finalized.

The record date for dividends is set for the 10th of next month. Interim dividends will be paid to shareholders registered in the shareholder registry as of that date before the 31st of next month.

SK Co., Ltd. is focusing on investments and strengthening the competitiveness of its major subsidiaries in four key areas: Advanced Materials, Bio, Green, and Digital.

SK Powertech, which started mass production of SiC (Silicon Carbide) power semiconductors at its new Busan plant in the first half of this year, aims to triple its production capacity by the fourth quarter through plant optimization. SK Signet, a manufacturer of ultra-fast chargers, continues to increase its market share in the U.S. by completing its Texas plant and recently signing a large supply contract for over 1,000 units with an American company.

SK Pharmteco recently completed its second plant for innovative biopharmaceuticals, including cell and gene therapies, in France and is preparing for mass production early next year. Investment attraction to strengthen global competitiveness in the high-growth bio business is also progressing smoothly. SK Biopharm plans to secure growth engines in innovative new drugs such as radiopharmaceutical therapies and targeted protein degradation therapies, building on its success with epilepsy drugs.

In addition, SK Co., Ltd. is building a solid eco-friendly portfolio with high future value, including small modular reactors (SMR) and clean hydrogen, while continuing investments in digital technology areas such as AI (artificial intelligence) and Web3. Web3 refers to a form of the web where users own their data and personal information rather than having it controlled by platforms, granting data sovereignty to the users.

SK Co., Ltd. plans to continuously enhance financial soundness in preparation for macroeconomic uncertainties while focusing on strengthening business competitiveness to ensure that business performance translates into corporate value.

This content was produced with the assistance of AI translation services.